Skip to main content

Table 1 Characteristics of patients hospitalized and those not hospitalized within the 30 last days of life

From: Hospitalizations and re-hospitalizations at the end-of-life among cancer patients; a retrospective register data study

Demographic and clinical variables

Hospitalization within the last 30 days of life

Yes

No

 

n = 272 (%)

n = 111 (%)

p

Gender

 Male

178 (65%)

59 (53%)

0.025

 Female

94 (35%)

52 (47%)

Age at death (years)

 Mean

70

73

0.150

 Median

72

74

Patients with minor children

 Yes

21 (8%)

8 (7%)

0.863

 No

251 (92%)

103 (93%)

Primary malignancy

 Colorectal

52

30

 

 Pancreatic

42

13

 

 Prostate

40

14

 

 Breast

24

17

 

 Urothelial

18

5

 

 Bile duct

17

5

 

 Kidney

15

9

 

 Malignant melanoma

15

3

 

 Esophageal

14

2

 

 Ventricular

11

6

 

 Hepatic

8

0

 

 Cancer of unknown primary cite

6

5

 

 Others

10g

2h

 

Multiple primary malignancies

 Yes

13 (5%)

10 (9%)

0.114

 No

259 (95%)

101 (90%)

Anticancer treatment linesi

 Never treated

67 (25%)

41 (37%)

0.015

 Treated

205 (75%)

70 (63%)

 One line

79

38

 Two lines

62

10

 Three lines

24

8

 Four lines or greater

40

14

Anticancer treatment within the last 30 DOLj

 No

168 (62%)

86 (77%)

0.003

 Yes

104 (38%)

25 (23%)

 Chemotherapy

30ab

2

 Targeted therapy

22acd

2f

 Check-point-inhibitors

3

1

 Endocrine therapy

46bce

21

 Radiation therapy

18cde

0

Palliative care unit referral

 Yes

184 (68%)

79 (71%)

0.500

 No

88 (32%)

32 (29%)

Interval from PCU referral until death

 Mean (days)

99

181

< 0.001

 Median (days)

57

102

Use of PCU within the last 30 DOLj

 Yes

155 (57%)

46 (41%)

0.006

 No

117 (43%)

65 (59%)

Interval from diagnosis until death

 Mean (days)

677

763

0.471

 Median (days)

275

326

  1. aThree patients received both chemotherapy and targeted therapy
  2. bTwo patients received both chemotherapy and endocrine therapy 
  3. cFive patients received both targeted therapy and endocrine therapy
  4. dOne patient received both targeted therapy and radiation
  5. eFour patients received both endocrine therapy and radiation
  6. fOne patient received both targeted therapy and endocrine therapy
  7. gSeven patients with NEC (neuroendocrine carcinoma), two with NET (neuroendocrine tumor) and one with duodenal cancer
  8. hOne patient with NEC and one with sarcoma
  9. iEndocrine therapy included as treatment line
  10. jDays of life